SQN 400

Drug Profile

SQN 400

Alternative Names: Bacteriochlorin

Latest Information Update: 19 Jan 2016

Price : $50

At a glance

  • Originator Scotia Holdings
  • Developer biolitec; QuantaNova
  • Class
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer

Most Recent Events

  • 22 Jan 2002 QuantaNova has the photodynamic therapy assets of Scotia Holdings
  • 03 May 2000 Scotia has signed an agreement with Techniclone Corporation giving Scotia exclusive rights to the latter's vascular targeting agents
  • 20 Oct 1999 Phase-I clinical trials for Liver cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top